Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,242Revenue (TTM) $M23.4Net Margin (%)-246.4Altman Z-Score6.4
Enterprise Value $M996EPS (TTM) $-0.8Operating Margin %-250.2Piotroski F-Score3
P/E(ttm)--Beneish M-Score-0.9Pre-tax Margin (%)-246.4Higher ROA y-yN
Price/Book6.410-y EBITDA Growth Rate %0.9Quick Ratio6.1Cash flow > EarningsY
Price/Sales45.35-y EBITDA Growth Rate %9.4Current Ratio6.1Lower Leverage y-yN
Price/Free Cash Flow101y-y EBITDA Growth Rate %--ROA % (ttm)-30.9Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-38.0Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M83.6ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with SGMO

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

SGMO is held by these investors:



SGMO: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Herberts Curt A. IIISr.VP & Chief Business Officer 2017-10-02Sell15,000$15.25-2.62view
RINGO WILLIAM RDirector 2017-09-20Sell31,000$14.373.34view
Herberts Curt A. IIISr.VP & Chief Business Officer 2017-09-01Sell15,000$15-1view
Herberts Curt A. IIISr.VP & Chief Business Officer 2017-08-14Sell11,474$10.4442.24view
Herberts Curt A. IIISr.VP & Chief Business Officer 2017-07-14Sell15,000$1048.5view
Herberts Curt A. IIISenior VP & CBO 2017-06-01Sell2,000$6.8118.38view
Herberts Curt A. IIISenior VP & CBO 2017-05-12Sell2,639$8.0285.16view
LANPHIER EDWARD O IIPresident & CEO 2015-07-15Sell25,000$10.4342.38view
Wolff Henry WardExec VP & CFO 2015-07-13Sell12,000$1048.5view
LANPHIER EDWARD O IIPresident & CEO 2015-06-15Sell25,000$11.0834.03view

Quarterly/Annual Reports about SGMO:

News about SGMO:

Articles On GuruFocus.com
Sangamo And Bioverativ Announce FDA Acceptance Of IND Application For ST-400 -- A Gene-Edited Cell T Oct 02 2017 
Sangamo Therapeutics Announces Participation At Upcoming Investor And Industry Conferences Sep 28 2017 
Sangamo Therapeutics Announces Presentation At The 2017 Cantor Fitzgerald Global Healthcare Conferen Sep 20 2017 
Sangamo Presents T Cell Engineering Capabilities at Immuno-Oncology Summit Aug 31 2017 
Sangamo Therapeutics Announces Presentations At Upcoming Investor Conferences Aug 30 2017 
Sangamo And Pfizer Announce First Patient Receives Treatment In Phase 1/2 Clinical Trial Evaluating Aug 25 2017 
Sangamo Therapeutics Announces Presentation At The 2017 Wedbush PacGrow Healthcare Conference Aug 10 2017 
Sangamo Therapeutics Reports Second Quarter 2017 Financial Results Aug 09 2017 
Sangamo Therapeutics Announces Second Quarter 2017 Conference Call And Webcast Aug 02 2017 
Sangamo Receives Fast Track Designation From The FDA For SB-318 And SB-913 In Vivo Genome Editing Pr Jul 13 2017 
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK